Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

Acceptance of abstracts highlights Nexalin's innovative DIFS™ treatment platform, delivering 15 mA at 77.5 Hz. Clinical studies demonstrate significant enhancements in anxiety, depression, insomnia, and overall quality of life.